Optimisation of medications used in residential aged care facilities: a systematic review and meta-analysis of randomised controlled trials

Background: Frail older adults living in residential aged care facilities (RACFs) usually experience comorbidities and are frequently prescribed multiple medications. This increases the potential risk of inappropriate prescribing and its negative consequences. Thus, optimising prescribed medications in RACFs is a challenge for healthcare providers. Objective: Our aim was to systematically review interventions that increase the appropriateness of medications used in RACFs and the outcomes of these interventions. Methods: Systematic review and meta-analysis of randomised control trials (RCTs) and cluster randomised control trials (cRCTs) were performed by searching specified databases (MEDLINE, PubMed, Google scholar, PsycINFO) for publications from inception to May 2019 based on defined inclusion criteria. Data were extracted, study quality was assessed and statistically analysed using RevMan v5.3. Medication appropriateness, hospital admissions, mortality, falls, quality of life (QoL), Behavioural and Psychological Symptoms of Dementia (BPSD), adverse drug events (ADEs) and cognitive function could be meta-analysed. Results: A total of 25 RCTs and cRCTs comprising 19,576 participants met the inclusion criteria. The studies tested various interventions including medication review (n = 13), staff education (n = 9), multi-disciplinary case conferencing (n = 4) and computerised clinical decision support systems (n = 2). There was an effect of interventions on medication appropriateness (RR 0.71; 95% confidence interval (CI): 0.60,0.84) (10 studies), and on medication appropriateness scales (standardised mean difference = − 0.67; 95% CI: − 0.97, − 0.36) (2 studies). There were no apparent effects on hospital admission (RR 1.00; 95% CI: 0.93, 1.06), mortality (RR 0.98; 95% CI: 0.86, 1.11), falls (RR 1.06; 95% CI: 0.89,1.26), ADEs (RR 1.04; 95% CI: 0.96,1.13), QoL (standardised mean difference = 0.16; 95% CI:-0.13, 0.45), cognitive function (weighted mean difference = 0.69; 95% CI: − 1.25, 2.64) and BPSD (RR 0.68; 95% CI: 0.44,1.06) (2 studies). Conclusion: Modest improvements in medication appropriateness were observed in the studies included in this systematic review. However, the effect on clinical measures was limited to drive strong conclusions

A scoping review of the use and impact of telehealth medication reviews

Item does not contain fulltextBACKGROUND: Telehealth has been proposed as a mechanism to overcome the practical difficulties associated with conducting timely and efficient medication reviews particularly in rural and remote settings. OBJECTIVE: The aim was to examine the literature on the use and impact of telehealth-facilitated medication reviews. METHODS: A scoping review of the literature was conducted. Articles that reported medication reviews performed by telehealth were identified by searching the Pubmed, Embase, Cochrane Library and CINAHL databases to January 2019 and screened using predefined inclusion criteria. Data were extracted from included articles and synthesised narratively. Findings are reported using the PRISMA-ScR guidelines. RESULTS: Twenty-nine studies, including 15 descriptive and 14 quasi-experimental studies, met the inclusion criteria. Twenty studies were reports of the implementation and/or evaluation of a service and others were proof of concept, feasibility or pilot studies. Telehealth medication reviews, conducted as standalone interventions or as a part of team-based care, included medication order reviews, medication management, antimicrobial stewardship programs and geriatric services and were delivered to patients in outpatient (n = 15) or hospital (n = 12) settings, with one study conducted in residential care and one study across settings. Outcomes reported included process evaluation (n = 23), medication use (n = 8), costs (n = 6), clinical outcomes (n = 5), and healthcare use (n = 1). Positive impact was observed on clinical outcomes (e.g. reduction in haemoglobin A(1c)), medication use (e.g. reduction in antimicrobial medications) and costs (e.g. savings due to travel avoided). Good overall satisfaction with the interventions was seen in all studies that reported patient satisfaction. CONCLUSIONS: The current evidence suggests that telehealth medication review may be a feasible model for delivering these services and potentially can save costs and improve care. However, the level of evidence may not be sufficient to reliably inform practice and policy on telehealth-facilitated medication-reviews